Table 6.

Overall response rate (ORR) and median duration of progression‐free survival (PFS) at week 24 (phase II) among patients with non‐small‐cell lung cancer treated with ASP8273, by exon 19 deletion (ex19del) and L858R

	Ex19del+ (n = 49)	Ex19del− (n = 27)	L858R+ (n = 23)	L858R− (n = 53)
PFS months (95% CI)	8.1 (5.6, upper bound not reached)	5.6 (3.0, upper bound not reached)	5.6 (2.6, upper bound not reached)	8.1 (5.7, upper bound not reached)
ORR (95% CI)	47% (32.5, 61.7)	33% (16.5, 54.0)	35% (16.4, 57.3)	45% (31.6, 59.6)

CI, confidence interval; –, upper bound not reached.